Introduction: Combining long-acting muscarinic antagonists (LAMAs) and long-acting b 2 -agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action. The optimal dose for the fixed-dose combination of the LAMA tiotropium and the LABA olodaterol needed to be determined. In this phase II trial, the dose response of tiotropium on top of olodaterol was investigated in a free-dose combination, while other phase II studies have explored different doses of olodaterol on top of tiotropium, with both drugs delivered using the Respimat Ò inhaler. Methods: This was a double-blind incomplete crossover trial in which 233 patients with moderate or severe COPD were randomized to receive four out of eight free-dose combinations of olodaterol (5 or 10 lg) and tiotropium (1.25, 2.5, or 5 lg) or placebo for 4 weeks each. Primary end point was trough forced expiratory volume in 1 s (FEV 1 ) change from baseline (response) after 4 weeks.
INTRODUCTION
The two main classes of bronchodilator used in chronic obstructive pulmonary disease (COPD) are long-acting muscarinic antagonists (LAMAs) and long-acting b 2 -agonists (LABAs), and use of LAMA ? LABA combination in COPD is supported by international guidelines [1] .
Combining bronchodilators with complementary modes of action in COPD offers greater lung function benefits than individual agents, with similar tolerability and safety [2, 3] . A number of LAMA/LABA fixed-dose combinations (FDCs) are now available or in development for the treatment of COPD, and these combinations have shown improvements in lung function, exercise tolerance, and patient-reported outcomes compared to individual agents [3] .
Tiotropium is a well-established, once-daily LAMA for the maintenance treatment of COPD [4] . Olodaterol is a once-daily LABA with high b 2 selectivity and a fast onset of action [5, 6] that has demonstrated efficacy and tolerability in phase III trials [7] [8] [9] [10] and has been approved for use in COPD in the US, Europe, and several other countries. A clinical program investigating the efficacy and safety of the FDC of tiotropium ? olodaterol has been completed, and the FDC has been approved in the US and Canada for the treatment of COPD.
Often when combining drugs in an FDC, it is assumed that the optimal doses should reflect those of the registered components, although this may not always be the case [11] . Prior to the phase III program for the tiotropium ? olodaterol FDC, a novel approach was taken to test this assumption and a series of phase II dose-response trials was developed to determine the dose response of each component within the FDC.
Two phase II studies (1237. 4 [NCT00696020] and 1237.9 [NCT00720499]) investigated different doses of olodaterol 2-10 lg (1237.9: 2 or 5 lg; 1237.4: 2, 5, or 10 lg) when added to tiotropium 5 lg, compared to tiotropium monotherapy [12] . In the study presented here, the dose response of tiotropium when added to olodaterol as a free-dose combination was investigated to determine the doses to be studied in the phase III tiotropium ? olodaterol trials. Tiotropium 1.25, 2.5, and 5 lg were added to olodaterol 5 and 10 lg in free combination.
The doses of tiotropium were chosen to provide a robust evaluation of the most relevant part of its dose-response curve and the highest dose included-5 lg-is its licensed dose in the Respimat Ò inhaler as monotherapy. In this study, a free combination of tiotropium and olodaterol (i.e., using a separate Respimat device for each treatment rather than the combination of treatments being delivered via one device) was used rather than the FDC because an FDC for the lower dose of tiotropium was not available.
The objective of the study reported here was to identify the optimal once-daily doses of tiotropium and olodaterol administered in free combination via the Respimat inhaler in COPD in terms of lung function and tolerability after 4 weeks.
METHODS

Study Design
This was a randomized, double-blind, phase IIb, incomplete crossover trial (ClinicalTrials.gov #NCT01040403; 1237.18) conducted between February 2010 and February 2011. Patients were randomized to receive four out of eight combinations: olodaterol (5 or 10 lg) in combination with tiotropium (1.25, 2.5, or 5 lg) or placebo (in place of tiotropium) for 4 weeks each in a randomized order ( Fig. 1 ).
There was a washout period before screening and, following the screening visit, there was a 2-week run-in period prior to randomization to ensure clinical stability. In between each treatment period, there were 3-week washout periods and patients were evaluated for 3 weeks following the final dose of the last treatment.
The trial was carried out in compliance with Patients recorded the number of puffs of rescue medication they took during the day and at night in a diary. Patient's global rating was assessed at the end of each treatment period (before spirometry); patients rated their own respiratory health compared to the day before commencing each treatment period on a 7-point scale from ''very much better'' (1) to ''very much worse'' (7) . Physician's global evaluation was assessed on the first and last day of each treatment period; the investigator rated the patient's overall clinical condition from ''poor'' (1-2) to ''excellent'' (7) (8) .
All adverse events (AEs) were recorded at each visit. Clinical laboratory testing was conducted at screening and at the end of each treatment period, and a standard 12-lead electrocardiogram was performed at screening and at all treatment visits 30 and 40 min post-dose. Any abnormalities or worsening of baseline conditions were reported as AEs.
Study Outcomes
The primary end point was trough FEV 1 response (change from baseline) after 4 weeks of treatment. Trough FEV 1 was defined as the mean of the two pre-treatment FEV 1 values (at 1 h and 10 min before dosing, respectively) at the end of the dosing interval, and baseline FEV 1 was defined as the mean of the two pre-treatment FEV 1 values (1 h pre-dose and 10 min pre-dose) measured prior to administration of the first dose of study medication.
Secondary end points included trough FVC, FEV 1 , and FVC area under the curve from 0 to 6 h (AUC 0-6 ), mean weekly rescue medication use, physician's global evaluation, and patient's global rating. Incidence and severity of AEs were reported irrespective of causality, and pulse rate and blood pressure were recorded in conjunction with spirometry at 10 min pre-dose and 30 min post-dose.
Statistical Analysis
To detect a treatment difference of 0.050 L in trough FEV 1 
RESULTS
Patient Disposition and Baseline
Characteristics
In total, 283 patients were enrolled into the study and 233 were randomized to treatment. One randomized patient was withdrawn before receiving any medication due to an episode of atrial fibrillation. 
Efficacy
Lung Function
Trough FEV 1 responses with olodaterol 5 and 10 lg were 0.071 and 0.083 L, respectively, after 4 weeks of treatment. Trough FEV 1 responses increased with tiotropium ? olodaterol doses compared to olodaterol monotherapy after 4 weeks of treatment. Compared to olodaterol 5 lg monotherapy, the addition of tiotropium 1.25, 2.5, and 5 lg increased trough FEV 1 response by 0.054, 0.065, and 0.084 L, respectively, and compared to olodaterol 10 lg, the addition of tiotropium 1.25, 2.5, and 5 lg increased trough FEV 1 by 0.051, 0.083, and 0.080 L, respectively ( Table 2) .
The FEV 1 profiles after 4 weeks of treatment showed clear improvements with tiotropium ? olodaterol compared to olodaterol monotherapy and improvements in FEV 1 with increasing tiotropium doses on top of olodaterol 5 and 10 lg ( Fig.3 ). FEV 1 AUC 0-6 responses showed incremental increases with increasing dose of tiotropium with both olodaterol doses ( Table 2 ). The additional benefits from adding each dose of tiotropium to olodaterol were larger for FEV 1 AUC 0-6 than for trough FEV 1 although, in both cases, FEV 1 response was greater overall with the combination therapy compared to olodaterol ( Table 2) . The FVC profiles showed improvements with the addition of tiotropium to both olodaterol doses ( Fig. 4) and FVC AUC 0-6 and trough FVC results showed greater improvements with tiotropium ? olodaterol compared to olodaterol alone. Tiotropium added to olodaterol 5 lg showed increases in trough FVC between 0.099 and 0.120 L compared to olodaterol 5 lg, while tiotropium added to olodaterol 10 lg increased trough FVC by 0.127-0.131 L. FVC AUC 0-6 also increased with the addition of tiotropium 1.25, 2.5, and 5 lg compared to olodaterol 5 lg alone by 0.131-0.150 L, and added to olodaterol 10 lg by 0.179-0.213 L ( Table 3) .
Other Secondary End Points
Weekly mean rescue medication use decreased from baseline levels with all treatments after Patients generally rated their health as ''a little better'' on the patient's global rating after 
Safety
AEs are summarized in Table 4 ; the most common were nasopharyngitis and COPD exacerbation. AEs leading to discontinuation occurred in\2% of patients with any treatment.
The incidence of serious AEs is presented in Table 4 ; two patients died during the washout period following olodaterol 10 lg treatment.
Both deaths were caused by myocardial infarction and were not considered by investigators to be related to study drug. Across treatment arms, incidence of AEs was similar, with no increase in AEs for tiotropium ? olodaterol versus olodaterol or with increasing doses of tiotropium. There were no notable changes in vital signs with any treatment.
DISCUSSION
This trial demonstrated that the combination of tiotropium ? olodaterol delivered via the Respimat inhaler resulted in greater olodaterol FDC was well tolerated in these trials, with comparable AE incidence to monotherapy [13] .
This trial was part of a novel approach to dose finding with drug combinations, in which the dose response of each component within the FDC was explored to confirm whether it is the same as the dose response when used as monotherapy. The dose response of olodaterol alone was investigated in olodaterol dose-finding studies, which identified olodaterol 5 and 10 lg as the doses to be taken forward to the phase III trials [14] , and the dose response of tiotropium monotherapy in the Respimat inhaler has been investigated [15] , with 5 lg performing best and subsequently licensed in COPD. The present study was not powered to detect differences between different combined doses of tiotropium ? olodaterol, but it was sufficient to identify dose ordering for [16] .
The results showed that with this drug combination, it may have been acceptable to simply use the doses of each agent that are considered optimal as monotherapies. However, the preclinical studies had suggested that there may be some synergistic effect with the combination of tiotropium ? olodaterol at sub-optimal doses [17] and this is one of the reasons why this study was performed. It is not known whether this effect occurs in humans at sub-optimal doses, but it does not appear that the optimal dose of tiotropium ? olodaterol is any lower than the approved doses of the monotherapies. This study demonstrated that the most suitable combination of tiotropium ? olodaterol was at the licensed doses of the individual therapies; however, this result is specific to this combination of therapies and may not necessarily be the same for other combinations of therapies.
In addition to the main investigation of lung function in this study, a number of additional end points were included in the trial to explore the effects of the drug combination. [16] .
One potential limitation of the study is that, because the lower dose of tiotropium was not available in an FDC, the tiotropium ? olodaterol doses were administered as free-dose combinations in separate inhalers. However, it should be possible to extrapolate the results to the FDCs. As the formulations for the FDC are very similar to those used in the monotherapies, the differences in administration are minor (it takes only a little more time to use two inhalers rather than one) and compliance with two bronchodilators is generally relatively high. Another possible limitation is the lack of a placebo group, which may have further put the effect sizes into context. As this was not central to the primary objectives of the study, and there were already a large number of treatment arms, it was not possible. Phase III trials have subsequently investigated tiotropium ? olodaterol with a placebo arm [19] . The study also excluded patients with GOLD 4 COPD; again, these patients have been included in later phase III trials [16, 19] . 
